Soxitabs en es it fr

Soxitabs Brand names, Soxitabs Analogs

Soxitabs Brand Names Mixture

  • Pediazole (Erythromycin (Erythromycin Ethylsuccinate) + Sulfisoxazole Acetyl)
  • Renazone Plus Tab (Ammonium Chloride + Atropine Sulfate + Hyoscyamine Hydrobromide + Scopolamine Hydrobromide + Sulfisoxazole)

Soxitabs Chemical_Formula

C11H13N3O3S

Soxitabs RX_link

No information avaliable

Soxitabs fda sheet

Soxitabs msds (material safety sheet)

Soxitabs MSDS

Soxitabs Synthesis Reference

H. M. Wuest, M. Hoffer, U.S. pat. 2,430,094 (1947 to Hoffmann-La Roche)

Soxitabs Molecular Weight

267.305 g/mol

Soxitabs Melting Point

194 oC

Soxitabs H2O Solubility

0.13 mg/ml (25 oC)

Soxitabs State

Solid

Soxitabs LogP

2.569

Soxitabs Dosage Forms

Tablet; Oral suspension; Eye drops

Soxitabs Indication

Treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.

Soxitabs Pharmacology

Sulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Soxitabs Absorption

No information avaliable

Soxitabs side effects and Toxicity

LD50=6800 mg/kg (Orally in mice)

Soxitabs Patient Information

Soxitabs Organisms Affected

Enteric bacteria and other eubacteria